home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
TIME: Almanac 1990
/
1990 Time Magazine Compact Almanac, The (1991)(Time).iso
/
time
/
112789
/
11278900.024
< prev
next >
Wrap
Text File
|
1990-09-19
|
2KB
|
31 lines
MEDICINE, Page 56Brain DefenderA new drug slows the progress of Parkinson's disease
Among the greatest terrors of old age is the fear of becoming
physically crippled. About 600,000 Americans are afflicted with
Parkinson's disease, which is marked by a progressive dying off of
the brain cells that control voluntary movement. Victims suffer
from the shakes, muscle stiffness and poor balance; eventually,
many become totally disabled. Standard treatment for Parkinson's
has relied on giving patients levodopa. But the drug, which
supplies remaining brain cells with a vital chemical, simply
tempers the disease's symptoms without affecting its progress. Even
worse, the medication soon becomes ineffective. For that reason,
doctors wait as long as possible after the disease is diagnosed
before prescribing levodopa.
Now, though, a new drug called deprenyl may represent a turning
point in therapy for Parkinson's. Deprenyl's distinction: it
actually slows the progress of the illness. In fact, it is the
first medication ever to retard a chronic brain disorder. Deprenyl
or similar drugs could conceivably lead to advances in the
treatment of other neurological diseases, including Alzheimer's.
Researchers reported the conclusive proof of deprenyl's effect
on Parkinson's in last week's New England Journal of Medicine. In
a study at 28 U.S. and Canadian medical centers involving 800
patients, investigators found that those given deprenyl took
significantly more time to reach the point where they needed
levodopa than did those not receiving the drug. Based on the
results, the researchers project that patients on deprenyl can wait
twice as long -- about a year -- before taking levodopa.